News

Jim Cramer's Investment Insights: Focus on Lam Research and More

Jim Cramer's Investment Insights: Focus on Lam Research and More

Investing Insights from Jim Cramer

In a recent episode of CNBC's “Mad Money Lightning Round,” investment expert Jim Cramer highlighted a few key stocks to watch in the current market landscape. His notable recommendation was for investors to consider Lam Research Corporation (NASDAQ: LRCX), expressing his strong approval. Cramer stated, “I like it very much here,” signaling confidence in the company’s performance.

Lam Research's Strong Financial Performance

On its latest quarterly earnings call, Lam Research reported impressive results, with earnings amounting to 86 cents per share, surpassing analyst expectations of 80 cents. Additionally, the company cited quarterly revenues of $4.17 billion, which exceeded expectations of $4.051 billion and marked a substantial increase from the $3.482 billion reported in the same quarter last year. These results have solidified Lam's position as a leading player in its sector.

Market Reactions and Other Recommendations

When responding to inquiries about Suncor Energy Inc. (NYSE: SU), Cramer appeared cautious, indicating a reluctance to offer buying advice in the current environment, saying, “No shots are being given in this industry, I can't do that.” As Suncor approaches the release of its third-quarter financial results, investors await further clarity on its direction.

Spotlight on Oklo Inc.

Cramer also weighed in on Oklo Inc. (NYSE: OKLO), describing it as a “short squeeze” situation, stating, “I'm getting tired of the short squeezes.” This comment follows a recent approval by the U.S. Department of Energy for Oklo's design report concerning its Aurora fuel fabrication facility, indicating potential growth for the company.

Joby Aviation's Recent Developments

Regarding Joby Aviation, Inc. (NYSE: JOBY), Cramer remained optimistic, stating, “I think you're ok for now.” Just recently, Joby priced a public offering of $202 million, which will consist of 40 million common shares priced at $5.05 each. Such developments indicate a strategic push for growth in the bustling aerial mobility sector.

Avoiding QuantumScape

On the other hand, Cramer advised investors to “avoid” QuantumScape Corporation (NYSE: QS). QuantumScape reported a quarterly loss of 23 cents per share, aligning with analyst forecasts but still raising concerns about its viability in the fast-evolving battery technology market. Investors should consider this cautionary advice when deliberating their portfolios.

Understanding NetApp's Position

Cramer also endorsed NetApp, Inc. (NASDAQ: NTAP) stating, “I'm all in.” This endorsement follows NetApp’s announcement about expanding its strategic partnership with Google Cloud, showcasing its commitment to growth and innovation within the tech space amidst ongoing competition.

Recent Stock Movements

Investors should also be aware of the recent pricing movements in these stocks. Lam Research shares experienced a slight decline, falling 2.9% to settle at $75.45. Suncor's shares are down 1.3%, closing at $38.47, while Oklo shares surged an impressive 28.9%, reaching $24.50. Joby Aviation saw a modest gain of 2.1% to $5.27. Conversely, QuantumScape shares dropped 8.1% to $5.69, indicating some bearish sentiment, while NetApp gained 0.8% to close at $120.41.

Frequently Asked Questions

What stocks did Jim Cramer recommend recently?

Jim Cramer recommended Lam Research Corporation (LRCX) and NetApp Inc. (NTAP) while advising caution on QuantumScape (QS) and Suncor Energy (SU).

What are the latest earnings results for Lam Research?

Lam Research reported earnings of 86 cents per share, exceeding analyst estimates, with quarterly revenues of $4.17 billion.

Why did Cramer advise against QuantumScape?

Cramer advised avoiding QuantumScape due to their recently reported quarterly loss of 23 cents per share, which matched expectations but raised concerns about future performance.

What is notable about Oklo Inc.

Oklo is recognized as a short squeeze scenario, and it recently received approval from the U.S. Department of Energy for its Aurora fuel fabrication facility.

How did the stocks perform on the market recently?

Recent market movements showed Lam Research down 2.9%, Suncor down 1.3%, with Oklo surging by 28.9% in value.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 6

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 8

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading

Top 5 Most Recently Viewed Articles

HeartCore's Journey: From Nasdaq Challenges to Growth Potential

Updated Category News Views 35

HeartCore's Nasdaq Delisting Challenge HeartCore Enterprises, Inc. (NASDAQ:HTCR), a provider of enterprise software and consulting services, is currently facing a significant challenge related to its listing on the Nasdaq Capital Market. The company has received notice of non-compliance with the minimum bid price requirement, which mandates that its stock price must be at...

Continue Reading
Mitchell Capital Expands Portfolio with Optelos Acquisition

Updated Category News Views 236

Mitchell Capital's New Acquisition of Optelos Mitchell Capital, a prominent private equity firm, recently announced a significant acquisition that marks a pivotal moment for their long-term investment strategy. They have secured a controlling interest in Optelos, a distinguished provider of digital twin platforms that are tailored for enhancing critical infrastructure...

Continue Reading
Tampa Bay Lightning and Scripps Sports Forge Exciting Partnership

Updated Category News Views 247

Partnership Announcement Between Tampa Bay Lightning and Scripps Sports The Tampa Bay Lightning have officially entered into an exciting multi-year partnership with Scripps Sports. This collaboration signifies a new chapter for the Tampa Bay Lightning, expanding their reach in broadcasting and enhancing viewer engagement with National Hockey League (NHL) games. Through...

Continue Reading
Kazia Therapeutics Sets Meeting with FDA on Glioblastoma Treatment

Updated Category News Views 61

Kazia Therapeutics Prepares for FDA Meeting on Paxalisib Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is set to meet with the U.S. Food and Drug Administration (FDA) to explore potential pathways for the registration of its innovative drug, Paxalisib, aimed at treating newly diagnosed glioblastoma multiforme (GBM). This crucial...

Continue Reading
Important Notice for Flux Power Investors on Lead Plaintiff Claims

Updated Category News Views 100

Overview of Flux Power Investor Claims Investors with concerns regarding their investments in Flux Power Holdings, Inc. (NASDAQ: FLUX) have much to consider as recent developments unfold. The national securities law firm, Faruqi & Faruqi, LLP, is actively investigating claims that could impact investor interests and is eager to assist those affected. Critical Investment...

Continue Reading